Immunoprofiling in poorly differentiated non-small cell lung cancer, analysis of data in a tertiary care center
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251631Keywords:
Immunohistochemistry, Squamous cell carcinoma, p63, TTF-1, Adenocarcinoma, Napsin-AAbstract
Background: Lung cancer is a leading cause of cancer-related deaths worldwide, including India, where it accounts for 5.9% of cancer cases and 8.1% of cancer-related mortality. Differentiating between major histologic subtypes of non-small cell lung carcinoma (NSCLC)-adenocarcinoma (ACA) and squamous cell carcinoma (SCC) is crucial due to significant differences in treatment response. Our study addresses the IHC profile of NSCLC in a tertiary care centre in South India. We have also deliberated whether a 2 panel IHC markers would be sufficient for the final diagnosis in a resource poor setting as compared to the traditional 4 IHC panel.
Methods: A hospital-based cross-sectional study (2018-2022) analysed 319 histologically confirmed poorly differentiated NSCLC cases. IHC markers (TTF-1, Napsin A, p63 and p40) were used for subtyping per WHO classification. Staining patterns were semi-quantitatively scored against controls. Sensitivity, specificity, PPV, NPV, and overall accuracy were calculated. Data analysis was performed using SPSS v23.
Results: Of the 319 cases, ACA was the most common (65.2%), followed by SCC (31.03%). Males accounted for 81.2% of cases, with the peak incidence in the 62-66 age group. For ACA, TTF-1 had higher sensitivity (97.17%) compared to Napsin A (83.49%), while Napsin A showed better specificity (96.04%). For SCC, p63 demonstrated higher sensitivity (93.07%) than p40 (78.22%), while p40 had better specificity (89.62%).
Conclusions: The study highlights the need for tailoring the IHC panel to suit the histopathological specimen in order to clinch the final diagnosis. In finance effectiveness, two marker panel can also be used.
Metrics
References
Sunilkumar S, Bindu T, Kumbakara, Ratheesan B, Satheesan. Patterns of cancer at a tertiary cancer center in Kerala, India, based on 10-years of hospital-based cancer registry data: A retrospective observational study. Cancer Res Statistics Treatment. 2024;7(2):185-92. DOI: https://doi.org/10.4103/crst.crst_375_23
Bergamini C, Ferris RL, Xie J, Mariani G, Ali M, Holmes WC, et al. Bleeding complications in patients with squamous cell carcinoma of the head and neck. Head Neck. 2021;43(9):2844-58. DOI: https://doi.org/10.1002/hed.26772
Huang Y, Zhang L, Shi Y, Ma S, Liao M, Bai C, et al. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. Japanese J Clin Oncol. 2015;45(6):569-75. DOI: https://doi.org/10.1093/jjco/hyv036
Tomasini P, Barlesi F, Mascaux C, Greillier L. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Therapeutic Adv Med Oncol. 2016;8(3):198-208. DOI: https://doi.org/10.1177/1758834016644155
Ofiara LM, Navasakulpong A, Ezer N, Gonzalez AV. The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment. Current Oncol. 2012;19(1):16-23. DOI: https://doi.org/10.3747/co.19.1062
Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, Fiegl M, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol. 2012;137(6):946-56. DOI: https://doi.org/10.1309/AJCP77KMKJXNMPMS
Yung RC, Otell S, Illei P, Clark DP, Feller-Kopman D, Yarmus L, et al. Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathol. 2012;120(3):185-95. DOI: https://doi.org/10.1002/cncy.20199
Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathol. 2011;24(10):1348-59. DOI: https://doi.org/10.1038/modpathol.2011.92
Fatima N, Cohen C, Lawson D, Siddiqui MT. TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol. 2011;119(2):127-33. DOI: https://doi.org/10.1002/cncy.20135
Johnson H, Cohen C, Fatima N, Duncan D, Siddiqui MT. Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma. Acta Cytologica. 2012;56(6):596-602. DOI: https://doi.org/10.1159/000339793
Sethi S, Geng L, Shidham VB, Archuletta P, Bandyophadhyay S, Feng J, et al. Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens. Cytojournal. 2012;9:10. DOI: https://doi.org/10.4103/1742-6413.94570
Brown AF, Sirohi D, Fukuoka J, Cagle PT, Nicolas M, Tacha D, et al. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. Arch Pathol Lab Med. 2013;137(9):1274-81. DOI: https://doi.org/10.5858/arpa.2012-0635-OA
Mohan A, Garg A, Gupta A, Sahu S, Choudhari C, Vashistha V, et al. Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. Lung India. 2020;37(3):190-7. DOI: https://doi.org/10.4103/lungindia.lungindia_333_19
Balakrishnan N, Jyothi CR. Immunohistochemical Profile in Lung Carcinoma. J Med Sci Clin Res. 20186(9)1022-6.
Shankar S, Thanasekaran V, Dhanasekar T, Duvooru P. Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India. Lung India. 2014;31(1):23-8. DOI: https://doi.org/10.4103/0970-2113.125889
Mandal SK, Singh TT, Sharma TD, Amrithalingam V. Clinico-pathology of lung cancer in a regional cancer center in Northeastern India. Asian Pacific J Cancer Prevent. 2013;14(12):7277-81. DOI: https://doi.org/10.7314/APJCP.2013.14.12.7277
Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136(5):504-9. DOI: https://doi.org/10.5858/arpa.2011-0618-RA
Kaur H, Sehgal IS, Bal A, Gupta N, Behera D, Das A, et al. Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer. 2017;54(1):285-90. DOI: https://doi.org/10.4103/ijc.IJC_597_16
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/ American thoracic society/ European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol. 2011;6(2):244-85. DOI: https://doi.org/10.1097/JTO.0b013e318206a221
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-54. DOI: https://doi.org/10.1016/S0140-6736(21)00312-3
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thoracic Oncol. 2015;10(9):1243-60. DOI: https://doi.org/10.1097/JTO.0000000000000630
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432-40. DOI: https://doi.org/10.1016/S0140-6736(09)61497-5
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-91. DOI: https://doi.org/10.1200/JCO.2004.11.022
Folpe AL, Gown AM, Lamps LW, Garcia R, Dail DH, Zarbo RJ, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Modern Pathol. 1999;12(1):5-8.
Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathol. 2012;25(3):405-15. DOI: https://doi.org/10.1038/modpathol.2011.173
Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415-20. DOI: https://doi.org/10.1046/j.1365-2559.2000.00890.x
Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Modern Pathol. 2006;19(8):1117-23. DOI: https://doi.org/10.1038/modpathol.3800629
Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, Napsin A, p63, and CK5/6. Am J Surgical Pathol. 2011;35(1):15-25. DOI: https://doi.org/10.1097/PAS.0b013e3182036d05
Ueno T, Linder S, Na CL, Rice WR, Johansson J, Weaver TE. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biological Chem. 2004;279(16):16178-84. DOI: https://doi.org/10.1074/jbc.M312029200
Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118(6):441-9. DOI: https://doi.org/10.1002/cncy.20108
Zhang H, Liu J, Cagle PT, Allen TC, Laga AC, Zander DS. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Modern Pathol. 2005;18(1):111-8. DOI: https://doi.org/10.1038/modpathol.3800251
Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis-a review of the physiological and pathological role of p63. Acta Cytologica. 2013;57(1):1-8. DOI: https://doi.org/10.1159/000345245
Nonaka D. A study of ΔNp63 expression in lung non-small cell carcinomas. Am J Surgical Pathol. 2012;36(6):895-9. DOI: https://doi.org/10.1097/PAS.0b013e3182498f2b
Tacha D, Bremer R, Haas T, Qi W. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers. Arch Pathol Lab Med. 2014;138(10):1358-64. DOI: https://doi.org/10.5858/arpa.2013-0342-OA
Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34(12):1805-11. DOI: https://doi.org/10.1097/PAS.0b013e3181f7dae3
Downloads
Published
How to Cite
Issue
Section
